These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1556 related articles for article (PubMed ID: 31016879)

  • 61. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
    J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
    Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
    Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
    Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
    Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Gene Expression and Clinical Characteristics of Molecular Targeted Therapy 
in Non-small Cell Lung Cancer Patients in Shandong].
    Qiao X; Ai D; Liang H; Mu D; Guo Q
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):14-20. PubMed ID: 28103968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
    Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
    Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
    Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
    Giroux Leprieur E; Antoine M; Vieira T; Duruisseaux M; Poulot V; Rabbe N; Belmont L; Gounant V; Lavolé A; Milleron B; Lacave R; Cadranel J; Wislez M
    Lung Cancer; 2013 Feb; 79(2):167-72. PubMed ID: 23153658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.